Lianbio
Clinical Trials
7
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
- Conditions
- Gastroesophageal Junction AdenocarcinomaGastric Cancer
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- LianBio LLC
- Target Recruit Count
- 6
- Registration Number
- NCT06206278
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Beijing Cancer Center, Beijing, Beijing, China
BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- LianBio LLC
- Target Recruit Count
- 4
- Registration Number
- NCT06032936
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China
🇨🇳Jilin Cancer Hospital, Changchun, Jilin, China
Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- LianBio LLC
- Target Recruit Count
- 163
- Registration Number
- NCT05629390
- Locations
- 🇨🇳
Beijing Tongren Hospital, Beijing, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Chongqing Aier Eye Hospital, Chongqing, Chongqing, China
Phase I Study of the BBP-398 in Patients With Advance Solid Tumors
- Conditions
- Advanced Solid TumorAdvanced or Metastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- LianBio LLC
- Target Recruit Count
- 7
- Registration Number
- NCT05621525
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China
🇨🇳West China Hospital Sichuan University, Chengdu, Sichuan, China
A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
- Conditions
- Obstructive Hypertrophic Cardiomyopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-12-30
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- LianBio LLC
- Target Recruit Count
- 81
- Registration Number
- NCT05174416
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
- Prev
- 1
- 2
- Next